Regencell Bioscience (NASDAQ:RGC) Sees Large Volume Increase – Here’s Why

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares saw unusually-high trading volume on Wednesday. Approximately 234,856 shares changed hands during trading, a decline of 17% from the previous session’s volume of 283,209 shares. The stock last traded at $8.43 and had previously closed at $8.19.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on RGC. Wall Street Zen cut shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The business has a fifty day simple moving average of $6.04 and a two-hundred day simple moving average of $14.43.

Regencell Bioscience (NASDAQ:RGC) last released its quarterly earnings data on Wednesday, October 7th. The company reported ($0.01) earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

Several institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in shares of Regencell Bioscience in the 4th quarter worth about $92,000. Amundi bought a new position in Regencell Bioscience during the 1st quarter valued at about $219,000. Finally, Bank of America Corp DE lifted its holdings in Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares during the last quarter. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.